abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs
AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 21 days
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 5 wks
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 1 month
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 14 days
Datroway secures regulatory approvals in breast cancer across US and EU / 7 wks
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 1 month
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.